Top of this page
Skip navigation, go straight to the content

Newsroom Press Releases

Disposals of own shares

Brussels (Belgium), 25 September 2020 – 20:00 (CEST) – regulated information
In accordance with article 8:6 of the Royal Decree executing the Belgian Code of Companies and Associations, UCB SA/NV (“UCB” or the “Company) (Euronext Brussels: UCB) announces that, following exercises of stock options by members of its personnel, it has disposed of UCB shares OTC in view of deliveries of these shares to the relevant members of the personnel, within the framework of the Long Term Incentive Program of the UCB Group, as follows:

 


 

In addition to these exercises, on 23 September 2020, in accordance with the vesting rules under its LTI plans, UCB SA/NV has delivered for free a total of 2 355 UCB shares OTC to 2 members of the personnel of the Company and its subsidiaries. The highest independent bid price on Euronext Brussels on 23 September 2020 was € 100.40.

This press release is available on UCB SA/NV’s website via the following link.

Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com

Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news

 


Stay up-to-date on the latest news and information from UCB